Drug Trial Radar · NCT06324006
A Phase 1 Trial of LIB-01 in Healthy Participants.
Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 25, 2023
Primary completion
Apr 23, 2024
Study completion May 29, 2024
Sponsor
- Lead sponsor
- Dicot ABIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are: * How safe and tolerable is LIB-01 when given once or repeatedly at different dose levels. * What are the pharmacokinetic characteristics of LIB-01 Participants will receive LIB-01 and be followed up for safety and pharmacokinetics by: * Adverse events * ECG * Blood sampling for laboratory parameters and pharmacokinetic analysis
Conditions
- Erectile Dysfunction
Interventions
LIB-01Drug
LIB-01 oral suspension
PlaceboOther
Placebo oral suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
- To evaluate changes in vital signs in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
- To evaluate changes in ECG in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
- To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following multiple oral dosing of LIB-01.Time frame: 28 days
- To evaluate changes in vital signs in healthy male participants, following a multiple oral dosing of LIB-01.Time frame: 28 days
- To evaluate changes in ECG in healthy male participants, following multiple oral dosing of LIB-01.Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Consultants
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.